Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Proactive news headlines: Hemogenyx, Eden Research, Futura, Blencow, Coro, Emyprean and more

Futura Medical PLC (AIM:FUM, OTC:FAMDF) provided keen investors with further details about the US launch plans for its fast-acting gel for erectile dysfunction from blue-chip partner Haleon PLC.

The AIM-listed healthcare company said since yesterday, 1 September, Eroxon is now available for pre-order online for delivery next month.

Read more

88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) used today’s half-year financial report statement to give investors a rundown of its projects in Alaska, Texas, and Namibia.

Project Phoenix, in Alaska, remains a primary focus.

Read more

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has passed a significant milestone with the European Patent Office, which granted a patent for its Mesodermal Killer (MK) cell therapy.

This intellectual property protection covers 39 countries, including the UK and the EU, and solidifies the company’s position in the rapidly growing field of cell-based immunotherapy.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK